Value through InnovationAugust 30 2016

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim press releases. To quickly find all press releases on a specific topic, please use the search.

Press Release Archive

back 1 2 3 4 5 6 7 8 9 10
08.30.2016

Qualcomm and Boehringer Ingelheim Pharmaceuticals collaborate to add new digital technology to RESPIMAT® inhaler

08.29.2016

ESC Congress 2016 Late Breaking Science Registry: Latest Data on Pradaxa (dabigatran etexilate mesylate) Safety and Effectiveness Profile Show Low Rates of Bleeding and Stroke in NVAF Patients in Routine Clinical Care

08.25.2016

Boehringer Ingelheim and Duke Clinical Research Institute Expand Collaboration to Create Largest Patient Registry for Idiopathic Pulmonary Fibrosis (IPF)

08.15.2016

Boehringer Ingelheim Launches RE-VECTO Global Program to Capture Data on Praxbind® (idarucizumab) Usage in Clinical Practice

07.27.2016

First Study Initiated to Evaluate the Effect of Ofev® Treatment on Biomarkers that may Predict IPF Progression

07.25.2016

Boehringer Ingelheim stops LUX-Head & Neck 2 and 4 trials following pre-planned analysis from independent Data Monitoring Committee

07.19.2016

U.S. FDA expands indication for type 2 diabetes treatment
Synjardy® (empagliflozin/metformin hydrochloride) to include treatment-naïve adults

07.13.2016

Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer

06.28.2016

FDA Advisory Committee recommends approval of Jardiance® (empagliflozin) for cardiovascular indication in 12-11 vote

06.27.2016

New analysis of INPULSIS™ trials demonstrates efficacy of OFEV® (nintedanib) across a range of IPF patients using broader diagnostic criteria

back 1 2 3 4 5 6 7 8 9 10